SCHEMBL18085040

SCHEMBL18085040

c1ccc(CCC2c3[nH]c4ccccc4c3CCN2Cc2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
MAPT P10636 5/20 0.51
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
SIGMAR1 Q99720 3/20 0.51
NPC1 O15118 1/20 0.51
ADRA1D P25100 1/20 0.49
ADRA1A P35348 1/20 0.49
ADRA1B P35368 1/20 0.49
LMNA P02545 2/20 0.48
KDM4E B2RXH2 5/20 0.48
KIF11 P52732 1/20 0.48
POLB P06746 1/20 0.48
GAA P10253 2/20 0.47
MAPK1 P28482 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
ESR1 P03372 1/20 0.47
PGR P06401 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3240544 0.86 ESR1 (0.54) ALDH1A1MAPTMEN1KMT2ANPC1
SCHEMBL14629720 0.81 ADRA1D (0.52) ALDH1A1MAPTMEN1KMT2ASIGMAR1
SCHEMBL11478266 0.80 POLB (0.51) ALDH1A1MAPTMEN1KMT2ASIGMAR1
SCHEMBL11190706 0.76 ADRA2C (0.49) ALDH1A1MAPTMEN1KMT2ANPC1
SCHEMBL764647 0.75 KIF11 (0.58) KIF11
SCHEMBL23875966 0.73 KIF11 (0.63) MAPTMEN1KMT2ALMNAKDM4E
SCHEMBL13747991 0.73 MAPT (0.57) ALDH1A1MAPTMEN1KMT2ASIGMAR1
SCHEMBL18087743 0.72 GRIN2B (0.76)
SCHEMBL18085037 0.72 BRD3 (0.56) ADRA1DADRA1AADRA1BKDM4ENPSR1
SCHEMBL11479762 0.71 ESR1 (0.54) ALDH1A1MAPTMEN1KMT2ASIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160272572-A1 ADENYLYL CYCLASE INHIBITORS FOR NEUROPATHIC AND INFLAMMATORY PAIN PURDUE RESEARCH FOUNDATION 2016-09-22 US disclosed
US-20160272572-A1 ADENYLYL CYCLASE INHIBITORS FOR NEUROPATHIC AND INFLAMMATORY PAIN PURDUE RESEARCH FOUNDATION 2016-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160272572-A1 ADENYLYL CYCLASE INHIBITORS FOR NEUROPATHIC AND INFLAMMATORY PAIN ADCY1, ADCY2, ADCY5 ALDH1A1 1332/4885MAPT 2563/4885MEN1 3970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.